VOYAGER
Live / Allowed — Notice of allowance issued (as of 24 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 12 Aug 2021 filing date already counts against anyone who files later.
Record
- Serial number
- 90879826
- Mark type
- Stylized text
- Filed
- 12 Aug 2021
- Published for opposition
- 30 Dec 2025
- Attorney of record
- Keith Toms, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies; gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising biological compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics for gene therapy or for the treatment of neurological diseases and disorders; Drug delivery agents comprising biological preparations in the nature of capsids that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics for gene therapy or for the treatment of neurological diseases and disorders
- Class 042 — Scientific and technological services: Pharmaceutical research and development in the field of gene therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy; pharmaceutical research services; research and development of pharmaceutical preparations for gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research and development services in the field of platforms technologies for genetic delivery of therapies and pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development regarding the use of RNA-derived functional screening platforms to discover, research and develop novel capsids for genetic deliver of therapies and pharmaceuticals; research and development regarding the identification and targeting of specific cells and tissues for gene therapy delivery
- Class 044 — Medical, beauty and agricultural services: Medical treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease
Owner
- Voyager Therapeutics, Inc., Lexington, MA, US
- Voyager Therapeutics, Inc., Lexington, MA, US
Prosecution history
- 24 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Dec 2025 — PUBLISHED FOR OPPOSITION
- 24 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Dec 2025 — EXAMINER'S AMENDMENT ENTERED
- 05 Dec 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 05 Dec 2025 — EXAMINERS AMENDMENT E-MAILED
- 05 Dec 2025 — EXAMINERS AMENDMENT -WRITTEN
- 09 Sept 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 09 Sept 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 09 Jun 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 09 Jun 2025 — FINAL REFUSAL E-MAILED
- 09 Jun 2025 — FINAL REFUSAL WRITTEN
- 30 May 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION